Timothy J Hobday

Timothy J Hobday

UNVERIFIED PROFILE

Are you Timothy J Hobday?   Register this Author

Register author
Timothy J Hobday

Timothy J Hobday

Publications by authors named "Timothy J Hobday"

Are you Timothy J Hobday?   Register this Author

39Publications

1197Reads

46Profile Views

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

J Clin Oncol 2018 09 24;36(25):2621-2629. Epub 2018 Jul 24.

Kathy D. Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Anne O'Neill, Dana-Farber Cancer Institute, Boston, MA; William Gradishar, Northwestern University, Chicago; Nguyet Anh Le-Lindqwister, Heartland Cancer Research National Cancer Institute Community Oncology Research Program, Peoria, IL; Timothy J. Hobday, Mayo Clinic, Rochester; Stuart Bloom, Abbott Northwestern Hospital, Minneapolis, MN; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia; Adam M. Brufsky, University of Pittsburgh, Pittsburgh, PA; Ingrid A. Mayer, Vanderbilt University, Nashville, TN; Amye J. Tevaarwerk, University of Wisconsin, Madison, WI; Joseph A. Sparano, Montefiore Hospital and Medical Center, Bronx; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Carolyn B. Hendricks, Association Community Clinical Oncology Program, Bethesda, MD; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; and George W. Sledge JR, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118403PMC
September 2018

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

J Clin Oncol 2015 Aug 13;33(24):2623-31. Epub 2015 Jul 13.

Nancy U. Lin, Hao Guo, Nicole Ryabin, Julie S. Najita, William T. Barry, Ian E. Krop, Eric P. Winer, and Annick D. Van den Abbeele, Dana-Farber Cancer Institute; Andrea L. Richardson and Annick D. Van den Abbeele, Brigham and Women's Hospital, Boston, MA; Jeffrey T. Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Ingrid A. Mayer and Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN; Carla I. Falkson, University of Alabama, Birmingham, AL; Timothy J. Hobday, Mayo Clinic, Rochester, MN; E. Claire Dees, University of North Carolina, Chapel Hill, NC; Rita Nanda, University of Chicago, Chicago, IL; Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; and Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534525PMC
August 2015

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

J Clin Oncol 2015 May 8;33(14):1551-6. Epub 2014 Dec 8.

Timothy J. Hobday, Rui Qin, and Charles Erlichman, Mayo Clinic, Rochester, MN; Diane Reidy-Lagunes, Memorial Sloan Kettering Cancer Center, New York; Andreas Kaubisch, Montefiore Medical Center, Bronx, NY; Malcolm J. Moore, Princess Margaret Hospital, Toronto, Ontario, Canada; Jonathan Strosberg, H. Lee Moffitt Cancer Center, Tampa, FL; Manisha Shah, Ohio State University, Columbus, OH; Hedy Lee Kindler, University of Chicago, Chicago, IL; Heinz-Josef Lenz, University of Southern California, Los Angeles, CA; and Helen Chen, National Cancer Institute, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.2082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417726PMC
May 2015

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

J Natl Cancer Inst 2015 Mar 4;107(3). Epub 2015 Mar 4.

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (PJG); NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada (WRP, LES, BEC); NCIC Clinical Trials Group, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada (KAG); Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (JAL); Columbia University Medical Center, New York, NY (DLH); National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA (PR); Vanderbilt-Ingram Medical Center, Vanderbilt University Medical Center, Nashville, TN (IAM); Mayo Clinic College of Medicine, Rochester, MN (TJH); Centre de recherche du CHU de Québec, Unité de recherche en santé des populations Hôpital du Saint-Sacrement, Quebec, Quebec, Canada (JL); National Cancer Research Institute Breast Clinical Studies Group, London, UK (AMT); Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada (KIP); Juravinski Cancer Center at Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada (TJW, SDM); Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (HIC); British Columbia Cancer Agency, Fraser Valley Center, Surrey, British Columbia, Canada (CDO); University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada (KST); British Columbia Cancer Agency - Vancouver Island Center, University of British Columbia, British Columbia, Canada (VB); Ontario Cancer Institute, University Health Network, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (VS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565534PMC
March 2015

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

J Clin Oncol 2015 Jan 24;33(1):58-64. Epub 2014 Nov 24.

George T. Budd, Halle C. F. Moore, Cleveland Clinic, Cleveland; Timothy D. Moore, Mid Ohio Oncology Hematology, Columbus, OH; William E. Barlow, Danika L. Lew, SWOG Statistical Center; Kristine J. Rinn, Swedish Cancer Institute; Julie R Gralow, Seattle Cancer Care Alliance, Seattle, WA; Timothy J. Hobday Mayo Clinic, Rochester, MN; James A. Stewart, Baystate Medical Center, Springfield, MA; Claudine Isaacs, Georgetown University, Washington, DC; Muhammad Salim, Allan Blair Cancer Centre, Regina, Saskatchewan, Canada; Jonathan K. Cho, University of Hawaii MBCCOP, Honolulu, HI; Kathy S. Albain, Loyola University Chicago, Stritch School of Medicine; Chicago, IL; Helen K. Chew, University of California-Davis, Sacramento, CA; Gary V. Burton, Louisiana State University Health Sciences Center, Shreveport, LA; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Lawrence E. Flaherty, Karmanos Cancer Institute/Wayne State University, Detroit, MI; Bradley A. McGregor, Willford Hall Medical Center, Lackland Air Force Base; Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert B. Livingston, Arizona Cancer Center, Tucson, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.3296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268253PMC
January 2015

Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.

Pancreas 2014 Nov;43(8):1219-22

From the *Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ; †Division of Medical Oncology; and ‡Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000000234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267883PMC
November 2014

Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

Am J Clin Oncol 2014 Apr;37(2):167-71

*Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ †Research Services ‡Department of Oncology, Mayo Clinic, Rochester, MN §Department of Pathology, Medcenter One, Bismarck, ND ∥Missouri Baptist Cancer Center, St Louis, MO ¶Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e31826e0550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593738PMC
April 2014

Treatment of neuroendocrine tumor liver metastases.

Int J Hepatol 2012 25;2012:973946. Epub 2012 Nov 25.

Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/973946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512291PMC
December 2012

Medical management of pancreatic neuroendocrine tumors.

Am J Gastroenterol 2008 Feb 19;103(2):475-83; quiz 484. Epub 2007 Nov 19.

Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1111/j.1572-0241.2007.016
Publisher Site
http://dx.doi.org/10.1111/j.1572-0241.2007.01643.xDOI Listing
February 2008

Carcinoid heart disease.

Prog Cardiovasc Dis 2007 May-Jun;49(6):439-51

Division of Cardiovascular Diseases, Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pcad.2006.12.002DOI Listing
July 2007

A single-center experience with inflammatory breast cancer, 1985-2003.

Arch Surg 2006 Jun;141(6):567-72; discussion 572-3

Department of Surgery, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archsurg.141.6.567DOI Listing
June 2006

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.

Mayo Clin Proc 2005 Apr;80(4):502-6

Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4065/80.4.502DOI Listing
April 2005

Molecularly targeted therapies for breast cancer.

Cancer Control 2005 Apr;12(2):73-81

Department of Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/107327480501200202DOI Listing
April 2005

An overview of approaches to adjuvant therapy for colorectal cancer in the United States.

Authors:
Timothy J Hobday

Clin Colorectal Cancer 2005 Apr;5 Suppl 1:S11-8

Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
April 2005

Imatinib mesylate-induced interstitial pneumonitis.

Mayo Clin Proc 2003 Dec;78(12):1578-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4065/78.12.1578DOI Listing
December 2003

Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.

Clin Colorectal Cancer 2002 Nov;2(3):161-9

Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2002.n.021DOI Listing
November 2002

Adjuvant therapy of colon cancer: a review.

Clin Colorectal Cancer 2002 Feb;1(4):230-6

Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2002.n.004DOI Listing
February 2002